Skip to main content
. 2021 Jun 2;11:684396. doi: 10.3389/fonc.2021.684396

Table 1.

Association between ADM expression levels and clinical/molecular data across public datasets.

Variable GSE6891 (n=68) GSE14468 (n=459) Beat AML (n=142) TCGA-LAML (n=135)
n (%) median [min-max] p n (%) median [min-max] p n (%) median [min-max] p n (%) median [min-max] p
Age - 0.034 0.653 0.056
<60-years 383 (83.8) 159.8 [57.7-3848.3] 60 (42.3) 9.5 [0.2-313.9] 72 (53.3) 1.3 [0.0-23.1]
≥60-years 63 (100.0) 196.7 [93.4-4451.3] 74 (16.2) 238.2 [98.4-442.9] 82 (57.7) 11.4 [0.3-151.7] 63 (46.7) 2.0 [0.0-57.1]
missing 5 2
FAB 0.001 <0.001 0.057 0.591
M0 2 (3.6) 229.7 [188.7-270.6] 18 (4.1) 135.3 [80.5-477.7] 4 (7.8) 4.0 [1.2-6.1] 14 (10.5) 2.1 [0.0-5.5]
M1 11 (19.6) 122.7 [97.0-206.5] 97 (22.2) 134.8 [57.7-3396.9] 6 (11.8) 1.3 [1.0-118.2] 35 (26.1) 1.2 [0.0-12.4]
M2 23 (41.1) 148.1 [92.4-1024.0] 123 (28.2) 147.0 [71.0-2936.7] 5 (9.8) 6.4 [0.9-63.6] 38 (28.4) 1.3 [0.1-17.2]
M4 9 (16.1) 221.3 [172.4-4451.3] 83 (19.0) 205.1 [84.5-3848.3] 16 (31.4) 19.0 [3.5-159.1] 29 (21.6) 2.0 [0.1-12.8]
M5 10 (17.9) 448.6 [166.6-4451.3] 109 (24.9) 183.6 [83.9-4482.2] 19 (37.3) 4.3 [0.3-151.7] 15 (11.2) 1.1 [0.0-57.1]
M6 1 (1.8) 843.4 7 (1.6) 171.3 [123.6-849.2] 2 (1.5) 2.3 [1.9-2.7]
M7 1 (2.0) 5.9 1 (0.8) 1.4 [1.4-1.4]
missing 12 22 91 1
Cytogenetic group 0.063 <0.001 0.001 0.001
t(8;21) 3 (5.0) 104.0 [96.3-126.2] 32 (9.8) 137.2 [92.4-451.9] 3 (2.1) 7.3 [0.9-15.1] 7 (5.3) 0.2 [0.1-1.0]
inv(16)/t(16;16) 4 (6.7) 516.6 [182.3-2256.7] 33 (10.1) 210.1 [125.4-2164.8] 9 (6.4) 18.9 [5.1-98.7] 10 (7.6) 1.9 [1.2-7.0]
NK 23 (38.3) 188.7 [96.3-4451.3] 139 (42.4) 149.1 [57.7-3848.3] 75 (53.6) 7.5 [0.2-313.9] 60 (45.5) 1.2 [0.0-57.1]
CK 4 (6.7) 178.1 [92.4-4451.3] 27 (8.2) 133.4 [95.7-2740.1] 19 (13.6) 35.6 [1.2-130.8] 18 (13.6) 3.4 [0.3-17.2]
KMT2A-r 1 (1.7) 179.8 15 (4.6) 116.2 [84.5-1782.9] 8 (5.7) 2.0 [0.3-39.3] 8 (6.1) 0.5 [0.0-1.8]
Other 25 (41.7) 229.1 [114.6-2019.8] 82 (25.0) 169.5 [74.5-3304.0] 26 (18.6) 13.8 [0.4-159.1] 29 (22.0) 1.9 [0.0-12.8]
missing 8 131 2 3
FLT3-ITD 0.023 0.009 0.062 0.001
FLT3-ITD+ 18 (26.5) 145.5[96.3-1024.0] 112 (28.3) 144.5 [57.7-2091.0] 27 (20.3) 4.2 [0.4-118.2] 27 (20.5) 0.4 [0.0-23.1]
FLT3-ITD 50 (73.5) 247.3 [92.4-4451.3] 283 (71.7) 167.7 [68.1-3848.3] 106 (79.7) 14.5 [0.2-313.9] 105 (79.6) 1.9 [0.0-57.1]
missing 64 9 3
NPM1 status 0.127 0.249 0.064 0.034
NPM1-mut 20 (29.4) 151.2 [96.3-2019.8] 135 (34.2) 313.9 [57.7-3743.1] 37 (27.8) 4.2 [0.6-313.9] 38 (28.8) 0.6 [0.0-57.1]
NPM1-wt 48 (70.6) 244.0 [92.4-4451.3] 260 (65.8) 164.9 [68.1-3848.3] 96 (72.2) 13.8 [0.2-159.1] 94 (71.2) 1.8 [0.0-16.8]
missing 64 9 3
FLT3-ITD/NPM1 0.004 0.070 0.086 0.009
−/wt 40 (58.8) 244.7 [92.4-4451.3] 218 (55.2) 168.9 [68.1-3848.3] 81 (60.9) 15.1 [0.2-159.1] 84 (63.6) 2.0 [0.0-16.8]
+/wt 8 (11.8) 281.9 [97.0-1024.0] 42 (10.6) 147.5 [83.3-2091.0] 15 (11.3) 8.9 [0.4-118.2] 10 (7.6) 0.8 [0.2-12.4]
−/mut 10 (14.7) 305.0 [120.3-2019.8] 65 (16.5) 163.2 [71.0-3743.1] 25 (18.8) 9.4 [0.6-313.9] 21 (15.9) 1.5 [0.0-57.1]
+/mut 10 (14.7) 123.8 [96.3-166.6] 70 (17.7) 140.6 [57.7-1758.3] 12 (9.0) 2.7 [0.8-46.5] 17 (12.9) 0.3 [0.0-23.1]
missing 64 9 3
ELN 2010 0.448 0.255 0.104 0.114
Favorable 11 (18.3) 221.3 [96.3-2256.7] 115 (35.3) 172.4 [67.2-2179.8] 38 (27.1) 10.8 [0.5-313.9] 40 (30.8) 1.3 [0.0-57.1]
Int-I 19 (31.7) 148.1 [96.3-4451.3] 89 (27.3) 140.1 [57.3-3875.1] 49 (35.0) 7.7 [0.2-151.7] 37 (28.5) 1.2 [0.1-23.1]
Int-II 18 (30.0) 201.6 [117.8-2019.8] 74 (22.7) 160.9 [70.0-3327.0] 26 (18.6) 10.2 [0.3-159.1] 22 (16.9) 1.5 [0.0-12.8]
Adverse 12 (20.0) 237.3 [92.4-4451.3] 48 (14.7) 150.1 [83.7-2019.8] 27 (19.3) 21.8 [0.4-130.8] 31 (23.9) 2.8 [0.3-17.2]
missing 8 133 2 5

CK, complex karyotype; Int, Intermediate; ITD, internal tandem duplication; KMT2A-r, KMT2A-rearranged; min-max, minimum-to-maximum value; mut, mutated; n, number; NK, normal karyotype; p, p value; wt, wild-type.

p ≤ 0.05 are highlighted as bold text.